Clinical trials: Diffuse Parenchymal Lung Diseases
Sjögren's Disease, Interstitial Lung Disease
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
This study aims to evaluate the efficacy Telitacicept in patients with primary Sjögren's Disease with interstitial lung disease
- Trial name
- NCT07843381
- Testing
- Telitacicept 160mg, Conventional treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Idiopathic Pulmonary Fibrosis (IPF)
The Genetics of Pulmonary Fibrosis
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
- Trial name
- NCT03478553
- Testing
- Blood draw, Questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Pulmonary Sarcoidosis
A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis
The study proposes to evaluate the safety, tolerability, and efficacy of PD 0360324 in subjects with chronic pulmonary sarcoidosis inadequately treated with standard of care therapies.
- Trial name
- NCT01732211
- Testing
- PD 0360324, Normal Saline for injection
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
Idiopathic Pulmonary Fibrosis
Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis
The aims of this study are to determine whether neuromuscular stimulation (NMES) of the quadriceps muscle is acceptable to patients with Idiopathic Pulmonary Fibrosis (IPF) and staff and whether it can impact clinical and…
- Trial name
- MUST-IPF (NCT03499275)
- Testing
- Active NMES, Home exercise programme, Breathlessness advice
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Interstitial Lung Disease
Impact of Lung Boost Device on Ventilatory Functions and Fatigue in Patients With Interstitial Lung Diseases
The purpose of this study will be to determine the effect of lung boost exercise on ventilatory functions, fatigue, and physical function capacity in Interstitial lung disease patients.
- Trial name
- NCT06991153
- Testing
- Lung Boost Device Training, Traditional physical therapy program, Medical Treatment
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF)
Finger Versus Earlobe Pulse Oximetry During the 6-Minute Walk Test in Interstitial Lung Disease
The OXISITE-ILD study is a prospective, multicenter, observational study designed to evaluate the agreement between finger (digital) and earlobe (auricular) pulse oximetry for measuring oxygen saturation (SpO2) during the…
- Conditions
- Interstitial Lung Disease (ILD), Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis, Connective Tissue Disease-Associated Interstitial Lung Disease
- Trial name
- OXISITE-ILD (NCT07723872)
- Testing
- Dual-site pulse oximetry (finger and earlobe)
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Hospital de Granollers
COPD, Interstitial Lung Disease
MOBoxy: MoblO2 to Maintain Oxygenation
Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course.
- Trial name
- MOBoxy (NCT07222592)
- Testing
- MoblO2 control
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Jewish Health
Lung Diseases, Interstitial
A Trial of Tadalafil in Interstitial Lung Disease of Scleroderma
Systemic sclerosis (SSc, scleroderma) is a multisystem autoimmune rheumatic disease that causes inflammation, vascular damage and fibrosis. Besides involvement of skin, fibrosis also affects lung and heart.
- Trial name
- NCT01553981
- Testing
- Tadalafil
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Idiopathic Pulmonary Fibrosis
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
This is an active surveillance study to monitor the real world safety of nintedanib in Indian patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT03047031
- Testing
- Nintedanib, Pirfenidone
- Where
- 8 sites in India
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Fibrosing Interstitial Lung Diseases, Thoracic Ultrasound
Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease
In this study the investigators want to examine the different ultrasound techniques to assess the patients with lung fibrosis. The investigators want to followup these patients in 1 year to see the changes in lungs, pleura…
- Trial name
- LORD (NCT06844331)
- Testing
- Thoracic ultrasound
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Odense University Hospital
Stage 4 Pulmonary Sarcoidosis
Pulmonary Rehabilitation in Patients With Sarcoidosis
The primary objective of the study is to assess the improvement of daily activity in subjects with Stage IV Pulmonary Sarcoidosis one year after the conduct of a pulmonary rehabilitation program.
- Trial name
- NCT02044939
- Testing
- Pulmonary rehabilitation program
- Where
- 11 sites in France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Lille
Idiopathic Pulmonary Fibrosis
A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT02871401
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Vanderbilt University Medical Center
Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease (ILD), Suspected Interstitial Lung Disease, Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- OPTIMIZE-ILD-1 (NCT07482917)
- Testing
- Standard ILD Diagnostic Pathway, Optimized ILD Diagnostic Circuit
- Where
- Spain
- Volunteers
- 92 people
- Sponsor
- Hospital de Granollers
Silicosis
The SHIELD Whole Lung Lavage Study
An observational cohort study that will assess the efficacy of Whole Lung Lavage in workers with silicosis or silica-induced bronchitis.
- Trial name
- SHIELD (NCT05402176)
- Testing
- Whole Lung Lavage
- Where
- 4 sites in Australia
- Volunteers
- 30 people
- Sponsor
- The University of Queensland
Idiopathic Pulmonary Fibrosis
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment.
- Trial name
- NCT00189176
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Idiopathic Pulmonary Fibrosis
Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers
Patients with Idiopathic Pulmonary Fibrosis (IPF) and their caregivers will be randomized to receive this intervention or usual care.
- Trial name
- NCT02929017
- Testing
- SUPPORT, Currently Available Printed Material
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)
The primary objectives of this study are to determine the effect of simtuzumab (GS-6624) on progression-free survival (PFS) as determined by either a categorical decline in forced vital capacity (FVC) or all-cause mortality, in…
- Trial name
- RAINIER (NCT01769196)
- Testing
- Simtuzumab
- Where
- 175 sites in United States, Australia and 12 more
- Volunteers
- 544 people
- Sponsor
- Gilead Sciences
Interstitial Lung Disease, Sarcoidosis
Interstitial Lung Disease Research Unit Biobank
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Interstitial Lung Disease, Sarcoidosis, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis
- Trial name
- ILDRU (NCT05392881)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of Kansas Medical Center
Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore…
- Trial name
- NCT03500731
- Testing
- CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.